Menu
ETF
Annual · values20252024202320222021
Operating Cash Flow-1.79 M USD-16.07 M USD-1.34 M USD-1.04 M USD-316158 USD
Depreciation & Amortization
Stock-Based Compensation618974 USD1.19 M USD409595 USD
Capital Expenditures
Cash Flow from Investing4.96 M USD-273066 USD36.17 M USD-45.19 M USD
Cash Flow from Financing2.25 M USD12.79 M USD-35.56 M USD45.98 M USD
Dividends Paid
Stock Buybacks
Free Cash Flow-1.79 M USD-16.07 M USD-1.34 M USD-1.44 M USD-670820 USD

Estrella Immunopharma Inc. is a biotechnology company dedicated to the research and development of innovative therapies. Primarily focusing on creating advanced treatment options for cancer and other serious diseases, the company harnesses cutting-edge technologies to address unmet medical needs. Estrella Immunopharma operates within the highly impactful biopharmaceutical sector, where its contributions can have significant implications for healthcare treatments globally. With a commitment to scientific excellence, the company engages in the discovery of novel drug candidates, advancing them through rigorous clinical trials. Estrella Immunopharma is pivotal in translating scientific innovations into viable medical solutions, contributing to the growing field of personalized medicine. Its role in the market is significant, given the increasing demand for targeted therapies and advancements in medical technology. As a part of the pharmaceutical industry, it not only influences healthcare advancements but also impacts clinical practices, offering potential pathways to improve patient outcomes through novel and effective treatment modalities.